Antares Pharma Inc (NASDAQ:ATRS) has received an average rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, two have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $4.05.

Several analysts have commented on the stock. ValuEngine downgraded shares of Antares Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. BidaskClub upgraded shares of Antares Pharma from a “buy” rating to a “strong-buy” rating in a report on Monday, November 25th.

A number of hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System raised its holdings in Antares Pharma by 1.2% during the 3rd quarter. California State Teachers Retirement System now owns 252,023 shares of the specialty pharmaceutical company’s stock worth $843,000 after buying an additional 3,010 shares during the period. Commonwealth Equity Services LLC raised its holdings in Antares Pharma by 6.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 59,943 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 3,800 shares during the period. Prudential Financial Inc. raised its holdings in Antares Pharma by 33.8% during the 2nd quarter. Prudential Financial Inc. now owns 18,530 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 4,680 shares during the period. Envestnet Asset Management Inc. raised its holdings in Antares Pharma by 10.0% during the 3rd quarter. Envestnet Asset Management Inc. now owns 52,478 shares of the specialty pharmaceutical company’s stock worth $176,000 after buying an additional 4,780 shares during the period. Finally, Alpine Woods Capital Investors LLC raised its holdings in Antares Pharma by 60.0% during the 2nd quarter. Alpine Woods Capital Investors LLC now owns 16,000 shares of the specialty pharmaceutical company’s stock worth $53,000 after buying an additional 6,000 shares during the period. Hedge funds and other institutional investors own 38.62% of the company’s stock.

Shares of NASDAQ:ATRS traded up $0.07 during mid-day trading on Tuesday, reaching $4.89. The stock had a trading volume of 1,124,475 shares, compared to its average volume of 2,960,120. The firm has a market cap of $786.75 million, a PE ratio of -122.25 and a beta of 0.92. The firm has a 50 day simple moving average of $4.06 and a two-hundred day simple moving average of $3.40. The company has a current ratio of 2.95, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. Antares Pharma has a twelve month low of $2.53 and a twelve month high of $5.13.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. The business had revenue of $34.31 million for the quarter, compared to the consensus estimate of $26.36 million. Antares Pharma had a negative net margin of 0.56% and a negative return on equity of 1.40%. On average, equities analysts anticipate that Antares Pharma will post -0.04 EPS for the current fiscal year.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Further Reading: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.